Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study.

Autor: Majidova N; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Seyyar M; Department of Internal Medicine, Division of Medical Oncology, Kocaeli University, Kocaeli, Turkey., Bayraktar DI; Department of Internal Medicine, Division of Medical Oncology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey., Dinç G; Department of Internal Medicine, Division of Medical Oncology, Professor Dr Cemil Tascioglu City Hospital, Istanbul, Turkey., İsgandarov E; Department of Internal Medicine, Division of Medical Oncology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey., Huseynov J; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Yaşar A; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Çelebi A; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Sever N; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Kocaaslan E; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Erel P; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Ağyol Y; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Güren AK; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Arıkan R; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Işık S; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Ercelep Ö; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Demirağ G; Department of Internal Medicine, Division of Medical Oncology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey., Kefeli U; Department of Internal Medicine, Division of Medical Oncology, Kocaeli University, Kocaeli, Turkey., Köstek O; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Bayoğlu İV; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey., Sarı M; Department of Internal Medicine, Division of Medical Oncology, Marmara University School of Medicine, Istanbul, Turkey.

Publikováno v: Biomolecules & biomedicine [Biomol Biomed] 2024 Oct 17; Vol. 24 (6), pp. 1776-1784. Date of Electronic Publication: 2024 Oct 17.

Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.

Autor: Ünal Ç; Division of Medical Oncology, Department of Internal Medicine, Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Turkey., Azizy A; Division of Medical Oncology, Department of Internal Medicine, İstanbul University Institute of Oncology, İstanbul, Turkey., Karabulut S; Division of Medical Oncology, Department of Internal Medicine, İstanbul University Institute of Oncology, İstanbul, Turkey., Taştekin D; Division of Medical Oncology, Department of Internal Medicine, İstanbul University Institute of Oncology, İstanbul, Turkey., Akyıldız A; Division of Medical Oncology, Department of Internal Medicine, Hacettepe University Institute of Oncology, Ankara, Turkey., Yaşar S; Division of Medical Oncology, Department of Internal Medicine, Hacettepe University Institute of Oncology, Ankara, Turkey., Yalçın Ş; Division of Medical Oncology, Department of Internal Medicine, Hacettepe University Institute of Oncology, Ankara, Turkey., Çoban E; Division of Medical Oncology, Department of Internal Medicine, Uludağ University Hospital, Bursa, Turkey., Evrensel T; Division of Medical Oncology, Department of Internal Medicine, Uludağ University Hospital, Bursa, Turkey., Kalkan Z; Division of Medical Oncology, Department of Internal Medicine, Dicle University Hospital, Diyarbakır, Turkey., Oruç Z; Division of Medical Oncology, Department of Internal Medicine, Dicle University Hospital, Diyarbakır, Turkey., Derin S; Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa University Hospital, İstanbul, Turkey., Turna ZH; Division of Medical Oncology, Department of Internal Medicine, Cerrahpaşa University Hospital, İstanbul, Turkey., Bayram D; Division of Medical Oncology, Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey., Köş FT; Division of Medical Oncology, Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey., Şendur MAN; Division of Medical Oncology, Department of Internal Medicine, Ankara City Hospital, Ankara, Turkey., Sever N; Division of Medical Oncology, Department of Internal Medicine, Marmara University Hospital, İstanbul, Turkey., Ercelep Ö; Division of Medical Oncology, Department of Internal Medicine, Marmara University Hospital, İstanbul, Turkey., Seyyar M; Division of Medical Oncology, Department of Internal Medicine, Kocaeli University Hospital, Kocaeli, Turkey., Kefeli U; Division of Medical Oncology, Department of Internal Medicine, Kocaeli University Hospital, Kocaeli, Turkey., Uygun K; Division of Medical Oncology, Department of Internal Medicine, Kocaeli University Hospital, Kocaeli, Turkey., Özçelik M; Division of Medical Oncology, Department of Internal Medicine, Ümraniye Research and Training Hospital, İstanbul, Turkey., Ön S; Division of Medical Oncology, Department of Internal Medicine, Ege University Hospital, İzmir, Turkey., Şanlı UA; Division of Medical Oncology, Department of Internal Medicine, Ege University Hospital, İzmir, Turkey., Canaslan K; Division of Medical Oncology, Department of Internal Medicine, Dokuz Eylül University Hospital, İzmir, Turkey., Ünek İT; Division of Medical Oncology, Department of Internal Medicine, Dokuz Eylül University Hospital, İzmir, Turkey., Yücel KB; Division of Medical Oncology, Department of Internal Medicine, Gazi University Hospital, Ankara, Turkey., Özdemir N; Division of Medical Oncology, Department of Internal Medicine, Gazi University Hospital, Ankara, Turkey., Yazıcı O; Division of Medical Oncology, Department of Internal Medicine, Gazi University Hospital, Ankara, Turkey., Güzel HG; Division of Medical Oncology, Department of Internal Medicine, Antalya Research and Training Hospital, Antalya, Turkey., Salim DK; Division of Medical Oncology, Department of Internal Medicine, Antalya Research and Training Hospital, Antalya, Turkey., Göksu SS; Division of Medical Oncology, Department of Internal Medicine, Akdeniz University Hospital, Antalya, Turkey., Tatlı AM; Division of Medical Oncology, Department of Internal Medicine, Akdeniz University Hospital, Antalya, Turkey., Ordu Ç; Division of Medical Oncology, Department of Internal Medicine, Gayrettepe Florence Nightinagle Hospital, İstanbul, Turkey., Selvi O; Division of Medical Oncology, Department of Internal Medicine, Okmeydanı Research and Training Hospital, İstanbul, Turkey., Sakin A; Division of Medical Oncology, Department of Internal Medicine, Bahçelievler Medipol Hospital, İstanbul, Turkey., Büyükbayram ME; Division of Medical Oncology, Department of Internal Medicine, Ataturk University Hospital, Erzurum, Turkey., Dursun B; Division of Medical Oncology, Department of Internal Medicine, Ankara University Hospital, Ankara, Turkey., Ürün Y; Division of Medical Oncology, Department of Internal Medicine, Ankara University Hospital, Ankara, Turkey., Arak H; Division of Medical Oncology, Department of Internal Medicine, Gaziantep University Hospital, Gaziantep, Turkey., Ağdaş G; Division of Medical Oncology, Department of Internal Medicine, Osmangazi University Hospital, Eskişehir, Turkey., Uğraklı M; Division of Medical Oncology, Department of Internal Medicine, Konya Meram University Hospital, Konya, Turkey., Hendem E; Division of Medical Oncology, Department of Internal Medicine, Konya Meram University Hospital, Konya, Turkey., Eryılmaz MK; Division of Medical Oncology, Department of Internal Medicine, Konya Meram University Hospital, Konya, Turkey., Bilgin B; Division of Medical Oncology, Department of Internal Medicine, Konya City Hospital, Konya, Turkey., Topçu A; Division of Medical Oncology, Department of Internal Medicine, Bezmialem Vakıf University Hospital, İstanbul, Turkey., Şimşek M; Division of Medical Oncology, Department of Internal Medicine, Bezmialem Vakıf University Hospital, İstanbul, Turkey., Büyükşimşek M; Division of Medical Oncology, Department of Internal Medicine, Adana Research and Training Hospital, Adana, Turkey., Akay B; Division of Medical Oncology, Department of Internal Medicine, Ankara Yurtaslan City Hospital, Ankara, Turkey., Erdal GŞ; Division of Medical Oncology, Department of Internal Medicine, Bakırköy Sadi Konuk Research and Training Hospital, İstanbul, Turkey., Karataş F; Division of Medical Oncology, Department of Internal Medicine, Karabük University Hospital, Karabük, Turkey., Alan Ö; Division of Medical Oncology, Department of Internal Medicine, Koc University Hospital, İstanbul, Turkey., Çağlayan M; Division of Medical Oncology, Department of Internal Medicine, Konya Selçuk University Hospital, Konya, Turkey., Kahvecioğlu FA; Division of Medical Oncology, Department of Internal Medicine, Sakarya Research and Training Hospital, Sakarya, Turkey., Demirci A; Division of Medical Oncology, Department of Internal Medicine, Sakarya Research and Training Hospital, Sakarya, Turkey., Paksoy N; Division of Medical Oncology, Department of Internal Medicine, Tekirdağ City Hospital, Tekirdağ, Turkey., Çetin B; Division of Medical Oncology, Department of Internal Medicine, Ondokuz Mayıs University Hospital, Samsun, Turkey., Gümüş M; Division of Medical Oncology, Department of Internal Medicine, Göztepe Medeniyet University Hospital, İstanbul, Turkey., Ak N; Division of Medical Oncology, Department of Internal Medicine, İstanbul Florence Nightinagle Hospital, İstanbul, Turkey., Aydınalp Y; Division of Medical Oncology, Department of Internal Medicine, Adana Balcalı University Hospital, Adana, Turkey., Paydaş S; Division of Medical Oncology, Department of Internal Medicine, Adana Balcalı University Hospital, Adana, Turkey., Güven DC; Division of Medical Oncology, Department of Internal Medicine, Elazığ Fethi Sekin City Hospital, Elazığ, Turkey., Kılıçkap S; Division of Medical Oncology, Department of Internal Medicine, Ankara Liv Hospital, Ankara, Turkey., Sağlam S; Division of Medical Oncology, Department of Internal Medicine, Demiroglu Bilim University, İstanbul, Turkey.

Publikováno v: The oncologist [Oncologist] 2023 Oct 03; Vol. 28 (10), pp. 875-884.

The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study.

Autor: Yekedüz E; Faculty of Medicine Department of Medical Oncology, Ankara University, Cebeci, 06590, Ankara, Turkey.; Ankara University Cancer Research Institute, Ankara, Turkey., Tural D; Department of Medical Oncology, University of Health Sciences, Bakirköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey., Ertürk İ; Department of Medical Oncology, University of Health Sciences, Gülhane Education and Research Hospital, Ankara, Turkey., Karakaya S; Medical Oncology Department, University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey., Erol C; Faculty of Medicine, Department of Medical Oncology, Ankara Yıldırım Beyazıt University, Ankara, Turkey., Ercelep Ö; Faculty of Medicine, Department of Medical Oncology, Marmara University, Istanbul, Turkey., Arslan Ç; Faculty of Medicine, Department of Medical Oncology, İzmir University of Economics, İzmir, Turkey., Sever ÖN; Faculty of Medicine, Department of Medical Oncology, Gaziantep University, Gaziantep, Turkey., Kılıçkap S; Faculty of Medicine, Department of Medical Oncology, Hacettepe University, Ankara, Turkey.; Faculty of Medicine, Department of Medical Oncology, İstinye University, Istanbul, Turkey., Şentürk Öztaş N; Cerrahpaşa Faculty of Medicine, Division of Medical Oncology, İstanbul University-Cerrahpaşa, Istanbul, Turkey., Küçükarda A; Faculty of Medicine, Department of Medical Oncology, Trakya University, Edirne, Turkey., Can O; Department of Medical Oncology, University of Health Sciences, Prof. Dr. Cemil Taşçıoğlu City Hospital, Istanbul, Turkey., Öksüzoğlu B; Medical Oncology Department, University of Health Sciences Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital, Ankara, Turkey., Şendur MA; Faculty of Medicine, Department of Medical Oncology, Ankara Yıldırım Beyazıt University, Ankara, Turkey., Karadurmuş N; Department of Medical Oncology, University of Health Sciences, Gülhane Education and Research Hospital, Ankara, Turkey., Ürün Y; Faculty of Medicine Department of Medical Oncology, Ankara University, Cebeci, 06590, Ankara, Turkey. yukselurun@gmail.com.; Ankara University Cancer Research Institute, Ankara, Turkey. yukselurun@gmail.com.

Publikováno v: Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2022 Dec; Vol. 148 (12), pp. 3537-3546. Date of Electronic Publication: 2022 May 26.

Predictive value of ¹⁸ F-FDG PET/CT indices on extensive residual cancer burden in breast cancer patients treated with neoadjuvant chemotherapy.

Autor: Başoğlu T; Marmara University School of Medicine, Division of Medical Oncology, Istanbul, Turkey. Electronic address: basoglutugba@gmail.com., Özgüven S; Marmara University School of Medicine, Department of Nuclear Medicine, Istanbul, Turkey. Electronic address: drsozg@gmail.com., Özkan HŞ; Marmara University School of Medicine, Department of Pathology, Istanbul, Turkey. Electronic address: drshulyasahin@gmail.com., Çınar M; Marmara University School of Medicine, Department of Internal Medicine, Istanbul, Turkey. Electronic address: cinar.merve48@gmail.com., Köstek O; Edirne State Hospital, Division of Medical Oncology, Edirne, Turkey. Electronic address: osmankostek@hotmail.com., Demircan NC; Marmara University School of Medicine, Division of Medical Oncology, Istanbul, Turkey. Electronic address: ncdemircan@gmail.com., Arıkan R; Marmara University School of Medicine, Division of Medical Oncology, Istanbul, Turkey. Electronic address: dr_rukiyearikan@hotmail.com., Telli TA; Marmara University School of Medicine, Division of Medical Oncology, Istanbul, Turkey. Electronic address: tugbaakintelli@gmail.com., Ercelep Ö; Marmara University School of Medicine, Division of Medical Oncology, Istanbul, Turkey. Electronic address: ozlembalvan@yahoo.com., Kaya H; Marmara University School of Medicine, Department of Pathology, Istanbul, Turkey. Electronic address: hkaya@marmara.edu.tr., Öneş T; Marmara University School of Medicine, Department of Nuclear Medicine, Istanbul, Turkey. Electronic address: tones@marmara.edu.tr., Erdil TY; Marmara University School of Medicine, Department of Nuclear Medicine, Istanbul, Turkey. Electronic address: yerdil@marmara.edu.tr., Uğurlu MÜ; Marmara University School of Medicine, Department of General Surgery, Istanbul, Turkey. Electronic address: umit.ugurlu@marmara.edu.tr., Dane F; Marmara University School of Medicine, Division of Medical Oncology, Istanbul, Turkey. Electronic address: faysaldane@yahoo.com., Yumuk PF; Marmara University School of Medicine, Division of Medical Oncology, Istanbul, Turkey. Electronic address: fuldenyumuk@yahoo.com.

Publikováno v: Revista espanola de medicina nuclear e imagen molecular [Rev Esp Med Nucl Imagen Mol (Engl Ed)] 2022 May-Jun; Vol. 41 (3), pp. 171-178. Date of Electronic Publication: 2021 May 26.

Prognostic Value of Tissue-Resident Memory T Cells and Tumor Microenvironmental Features in Resected Pancreatic Adenocarcinoma

Autor: Başoğlu T; Department of Medical Oncology, Marmara University School of Medicine, İstanbul, Turkey, Akar KE; Department of Pathology, Marmara University School of Medicine, İstanbul, Turkey, Bağcı P; Department of Pathology, Marmara University School of Medicine, İstanbul, Turkey, Akgül Babacan N; Department of Medical Oncology, Bahrain Oncology Center, Al Sayh, Bahrain, Öztürk MA; Department of Medical Oncology, Bahçeşehir University School of Medicine, İstanbul, Turkey, Öztürk FE; Department of Internal Medicine, Marmara University School of Medicine, İstanbul, Turkey, Demircan NC; Department of Medical Oncology, Marmara University School of Medicine, İstanbul, Turkey, Arikan R; Department of Medical Oncology, Marmara University School of Medicine, İstanbul, Turkey, Akın Telli T; Department of Medical Oncology, Marmara University School of Medicine, İstanbul, Turkey, Ercelep Ö; Department of Medical Oncology, Marmara University School of Medicine, İstanbul, Turkey, Dane F; Department of Medical Oncology, Marmara University School of Medicine, İstanbul, Turkey, Yumuk PF; Department of Medical Oncology, Marmara University School of Medicine, İstanbul, Turkey

Publikováno v: Balkan medical journal [Balkan Med J] 2022 Jan 25; Vol. 39 (1), pp. 12-20. Date of Electronic Publication: 2021 Dec 20.